Advanced Search

Dealmaking and Financing: Mergers and Acquisitions in Key Markets

Authors

Lulu Pickering, Ph.D.

Spectrum -- July 2008

Introduction:

Billion-dollar deals. Hostile takeovers. Reverse mergers. Bidding wars. All of these are signs that Big Pharma is hungry for deals and is aggressively seeking, assessing, and consummating alliances on several fronts. No facet of the biotech, specialty, or generics industries is being ignored; no technology platform, clinical product, or research program is unexplored or unexamined. Dealmaking has become the driving force that is bolstering R&D pipelines and promulgating innovative technology throughout drug discovery and development. In this report, which focuses on mergers and acquisitions (M&As) in the 18-month period from January 2007 through June 2008, we detail deals, the strategies that drove them, and the likely future role of M&As.

Get the Answers You Need to Shape Your Strategy:

Multibillion-dollar M&As are not uncommon as Big Pharma and Big Biotech hunt for biologics, enabling technologies, and products to bolster specific therapy areas. What are the forces driving these acquisitions and the industry trends that are developing? Which companies are moving to become leaders in personalized medicine and biosimilars?

Companies are evolving to become "hybrids" that have a hand in various market sectors, such as branded pharmaceuticals, generics, and biosimilars. What is the value of this strategy? Which companies are pursuing it, and how successful have they been? What, according to our expert commentator, does the Daiichi Sankyo/Ranbaxy deal reveal about this trend?

China has been identified as a national market that will become a center of gravity for the pharmaceutical industry in the near future. How are foreign investors tapping this potential? What activities are native Chinese pharmaceutical companies pursuing? How is the traditional Chinese medicines (TCM) market evolving? What does our expert commentator point out about opportunities in China?

M&As are likely to remain a valuable strategy in the pharmaceutical and biotech dealmaking arsenal. What are five key likely developments that will sustain the wave of M&As over the next few years?

Scope:

Key markets: technology types, therapeutic areas, drug types (biologics, biosimilars, generics), geographic markets.

Tables: ten tables detail M&A activity on a variety of fronts: billion-dollar deals, technology-driven deals, therapeutic-area-focused deals, IPO-less acquisitions, company type (big pharma, big biotech, specialty pharma, generics), and more.

Expert Commentaries: Greg B. Scott, founder and president, ChinaBio Accelerator and cofounder and president, Life Science Angels, discusses early-stage opportunities in China; Peter Wittner, Interpharm Consultancy, explores the future role of hybrid companies.

	Table of Contents
	Contact Sales to Purchase

Round-up
Register to receive the Round-up with our latest offers!

Companies:

3SBio

454 Life Sciences

Abbott

Abrika Pharmaceuticals

Actavis

Adaltis

Adams Respiratory Therapeutics

Adnexus

Agensys

Alantos Pharmaceuticals

Alcon

Allergan

Alliance BMP

Alliance Boots

Alnylam

American Oriental Bioengineering

AmeriPath

Amgen

Amgen-Dompe

Apotex

Apptec Laboratory Services

Arrow Therapeutics

Arysta LifeScience

Astellas Pharma

AstraZeneca

Axcan Pharma

AxiCorp

AXM Pharma Shenyang

Barr Pharmaceuticals

BASF

Bausch & Lomb

Bayer

Bayer Classics

Beckman Coulter

Beijing Boran Pharmaceutical

Beijing Med-Pharm

Beijing Tiancheng Haixin Pharmaceutical

Benda Pharmaceutical

Bentley Pharmaceuticals

Be-Tabs

Bio-Bridge Science

Biocon

Bioenvision

BioExplorer

Biogen Idec

BioRexis

Biosite

BioVeris

BioVitrum

BMP Sunstone

Boda

Boehringer Ingelheim

Borealis Infrastructure

Bradley Pharmaceuticals

Bristol-Myers Squibb

Celgene

Cerexa

Changchun Xinan Pharmaceutical

Charles River Laboratories

China Aoxing Pharmaceutical

China Bio

China BioPharma

China Biopharmaceuticals Holdings

China Gene

China Health Holdings

China Kelun Pharmaceutical

China Medical Technologies

China Nepstar

China Shenghuo Pharmaceutical Holdings

China Sky One Medical

ChinaBio Accelerator

Chiron

Chugai

CoGenesys

Coley Pharmaceutical Group

Covance

Cox Pharmaceuticals

CuraGen

CVC Capital

Cytyc

Dade Behring

Daiichi Sankyo

Dako

Digene

Domantis

Dompe Biotec

Dorom

Dr. Reddy’s Laboratories

Eisai

Eli Lilly and Company

Encysive Pharmaceuticals

EndoArt

EQT Partners

Esprit Pharma

Evans Medical

Forest Laboratories

Forum Bioscience Holdings

Fuji Photo Film Company

Fujifilm

Genentech

Generics UK

Genesis Pharmaceutical Enterprises

Genesis Technology Group

Genzyme

Gerber Products

GlaxoSmithKline

Greenstone

Guangxi Boke Pharmaceutical

Guangzhou Pharmaceutical

Guizhou Long-Life Pharmaceutical

Hainan CITIC Biopharmaceutical

Haptogen

Hebei Aoxing Pharmaceutical

Hebei Jiasheng Pharmaceutical & Chemical

Heilongjiang Tianlong Pharmaceutical

Henan Furen Huaiqingtang Pharmaceutical

Henan Tiankang Pharmaceutical

Hoechst

Hologic

Hong Kong Fly International Health Care

Human Genome Sciences

Hypnion

Icos

Ilypsa

Industrial Equity Investments

International Consolidated Companies

Interpharm Consultancy

Inverness Medical Innovations

Jet Generici

Kirin Brewery

Kyowa Hakko Kirin

Laiyang Jiangbo Pharmaceuticals

Lanzhou Roya Biotechnology

Lareq Pharma

Life Science Angels

Ligand Pharmaceuticals

Linkwell

Makiz

Matrix Laboratories

MDS Diagnostics

MediGene

MedImmune

Merck & Co.

Merck Darmstadt

Merck KGaA

Merck Serono

Meretek Diagnostics

MGI Pharma

Millennium Pharmaceuticals

Mindray Medical International

Mitsubishi Pharma

Mitsubishi Tanabe Pharma

Morphotek

MPI Research

Mundogen

Mylan Laboratories

Nanjing Tung Chit Pharmaceutical

Nestle

NeuTec Pharma

New River Pharmaceuticals

NimbleGen Systems

NM Generics

NovaCardia

Novartis

Nycomed Pharma

Organon BioSciences

Otsuka America Pharmaceutical

Paradigm Therapeutics

Paradigm Therapeutics Singapore

Pfizer

Pharmaceutical Enterprise

Pharmacia

Pharmion

Phynova

Piramed

PPD

Praecis Pharmaceuticals

Protez

Qiagen

Qinghai Pulante Pharmaceutical

Quest Diagnostics

Ranbaxy Laboratories

Reckitt Benckiser

Reliant Pharmaceuticals

Renaissance Capital

Renhuang Pharmaceuticals

Roche

Roche Diagnostics

Sandoz

Sanmar Specialty Chemicals

Sanofi-Aventis

Schein

Schering AG

Schering-Plough

Serenex

Shaanxi Mei Chen Pharmaceutical

Shaanxi Wanan Pharmaceutical

Shanghai Century

Shanghai Hua Tai Biotechnology

Shanghai Huaxin High Biotechnology

Shanghai Likang Biological High-Tech

Shanghai Rongheng Pharmaceutical

Shanghai Wanxing Bio-Pharmaceuticals

Shenzhen Mindray Medical

Shenzhen SiBiono GeneTech

Shijiazhuang Lerentang Pharmaceutical

Shire Pharmaceuticals

Sichuan Kelun Bio-Tech Pharmaceutical

Sichuan Kelun Pharmaceutical

Siemens

Simcere Pharmaceutical

Sinobiomed

Sirna Therapeutics

Sirtris Pharmaceuticals

Stada

Sun Pharmaceuticals

Sunstone Pharmaceutical

Suzhou Baoi

Syntonix Pharmaceuticals

Taisho Pharmaceutical

Takeda

Takeda Bio Development Center

Takeda Cambridge

Takeda Europe Holdings

Takeda San Francisco

Takeda Singapore

Taminco

Tanabe

Tanabe Seiyaku

Tanabe Seiyaku Hanabia

Tanox

TAP Pharmaceutical Products

Taro Pharmaceuticals

Teva Pharmaceutical Industries

The Dow Chemical Company

Therapeutic Human Polyclonals

Tianyuan Biotech

Tiens Biotech Group

Tongjitang Chinese Medicine

Topgen

Toyama Chemical

TPG

U3 Pharma

Ventana Medical Systems

Warburg Pincus

Watson Pharmaceuticals

WuXi PharmaTech

Wyeth

Xi’an Chunhui Pharmaceuticals

Xi’An Meichen Pharmaceutical

Yuhuatang Biological Sci-Tech Development

ZAO Biodyne Pharmaceuticals

ZAO Skopinpharm

ZAO-MAKIZ Pharma

Zenotech

Zentiva

Zhejiang Chiral Medicine Chemicals

Zhejiang Huahai Pharmaceutical

Zhejiang Tianyuan Bio-pharmaceutical

Zhongke Jinmeihua Biotech